StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 3,400 shares, a decline of 46.9% from the January 31st total of 6,400 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio is presently 0.3 days.

StageZero Life Sciences Price Performance

OTCMKTS SZLSF remained flat at $0.10 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.08 and a quick ratio of 0.04. The company's 50 day moving average price is $0.05 and its 200 day moving average price is $0.06. StageZero Life Sciences has a 1-year low of $0.04 and a 1-year high of $0.16.

About StageZero Life Sciences

(Get Rating)

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.

See Also

• Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
• Hormel Hits 2-Year Low, And The Dip Gets Bought
• Here's Why Ross Could Soon Be Hitting All Time Highs
• The Bottom Is In For Salesforce.com
• It's Time For A Fresh Look At The Kroger Co.
• West Fraser's Earnings Scream Timber, Outlook Says Buy

Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.